AVENUE THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Mar 18, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 18, 2024

ATXI$0.42-50.7%Stored close · as of Mar 18, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31,	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$1,783	$6,708
Prepaid expenses and other current assets	67	137
Total assets	$1,850	$6,845
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$287	$949
Accounts payable and accrued expenses - related party	323	21
Warrant liability	586	2,609
Total current liabilities	1,196	3,579
Total liabilities	1,196	3,579
Commitments and Contingencies (Note 6)
Stockholders’ equity
Preferred stock ($0.0001 par value), 2,000,000 shares authorized
Class A Preferred stock, 250,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively	—	—
Common stock ($0.0001 par value)
Common shares, 75,000,000 shares authorized and 25,597,622 shares issued and outstanding as of December 31, 2023; and 20,000,000 shares authorized and 4,773,841 shares issued and outstanding as of December 31, 2022	3	—
Additional paid-in capital	92,507	84,456
Accumulated deficit	(90,928)	(80,551)
Total stockholders’ equity attributed to the Company	1,582	3,905
Non-controlling interests	(928)	(639)
Total stockholders’ equity	654	3,266
Total liabilities and stockholders’ equity	$1,850	$6,845

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.